Cognos Therapeutics Appoints Innovobot U.S. Labs Executive Miguel Adao to Its Industry Advisory Board
Appointment reinforces Cognos’ commercialization strategy for SINNAIS, its AI-driven implantable drug delivery platform INGLEWOOD, CA, UNITED STATES, July 6, 2026 /EINPresswire.com/ -- Cognos Therapeutics (“Cognos”), a pioneering leader in AI- …